

REFERENCES

1. Ferlay J, Bray F, Pisani P, et al. (2004). GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5 Version 2.0. Lyon: International Agency for Research on Cancer. Available from: <http://www-dep.iarc.fr/> Date Accessed: November 12, 2008.
2. Spix C, Pastore G, Sankila R, et al. (2006). Neuroblastoma incidence and survival in European children (1978-1997): report from the Automated Childhood Cancer Information System project. *Eur J Cancer* 42: 2081-2091.
3. Gatta G, Ciccolallo L, Kunkler I, et al. (2006). Survival from rare cancer in adults: a population-based study. *Lancet Oncol* 7: 132-140.
4. Parkin DM, Ferlay J, Hamdi-Cherif M, et al. (2003). IARC Scientific Publications, Number 153, *Cancer in Africa: epidemiology and prevention*. Lyon, France: International Agency for Research on Cancer.
5. Parkin DM, Whelan SL, Ferlay J, Storm HH. Cancer Incidence in Five Continents, Vol. I to VIII IARC CancerBase No. 7, Lyon, 2005.
6. Ahmed F, Cardinez CJ, Jamison PM, et al. (2007). Cancer incidence in the USA, National Program of Cancer Registries (NPCR) 1998-2002. In: Curado MP, Edwards B, Shin HR, et al., eds, *IARC Scientific Publications, Number 160, Cancer incidence in five continents, Volume IX*. Lyon, France: International Agency for Research on Cancer. Available from: <http://www-dep.iarc.fr/> Date Accessed: November 12, 2008.
7. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P. (2007). IARC Scientific Publications, Number 160, *Cancer incidence in five continents, Volume IX*. Lyon, France: International Agency for Research on Cancer. Available from: <http://www-dep.iarc.fr/> Date Accessed: November 12, 2008.
8. WHO. (1992). *International statistical classification of diseases and related health problems : ICD-10*. Geneva: World Health Organization.
9. DiSario JA, Burt RW, Vargas H, et al. (1994). Small bowel cancer: epidemiological and clinical characteristics from a population-based registry. *Am J Gastroenterol* 89: 699-701.
10. Laurie SA and Licitra L (2006). Systemic therapy in the palliative management of advanced salivary gland cancers. *J Clin Oncol* 24: 2673-2678.
11. Goto M, Miller RW, Ishikawa Y, et al. (1996). Excess of rare cancers in Werner syndrome (adult progeria). *Cancer Epidemiol Biomarkers Prev* 5: 239-246.
12. Takazawa R, Ajima J, Yamauchi A, et al. (2004). Unusual double primary neoplasia: adrenocortical and ureteral carcinomas in werner syndrome. *Urol Int* 72: 168-170.
13. Lynch HT and Lynch JF (2004). Lynch syndrome: history and current status. *Dis Markers* 20: 181-198.
14. Frebourg T, Abel A, Bonaiti-Pellie C, et al. (2001). [Li-Fraumeni syndrome: update, new data and guidelines for clinical management]. *Bull Cancer* 88: 581-587.
15. Borch-Johnsen K, Olsen JH, Sorensen TI (1994). Genes and family environment in familial clustering of cancer. *Theor Med* 15: 377-386.
16. Levene S, Scott G, Price P, et al. (2003). Does the occurrence of certain rare cancers indicate an inherited cancer susceptibility? *Fam Cancer* 2: 15-25.
17. Kolstad H, Lynge E, Olsen J, et al. (1992). Occupational causes of some rare cancers. A literature review. *Scand J Soc Med Suppl* 48: 1-148.
18. Rowland RE, Stehney AF, Lucas HF, Jr. (1978). Dose-response relationships for female radium dial workers. *Radiat Res* 76: 368-383.
19. Creech JL and Johnson MN (1974). Angiosarcoma of liver in the manufacture of polyvinyl chloride. *J Occup Med* 16: 150-151.
20. Macbeth R (1965). Malignant disease of the paranasal sinuses. *J Laryngol Otol* 79: 592-612.
21. IARC (1979). *IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans, Volume 21, Sex hormones (II)*. Lyon, France: International Agency for Research on Cancer.
22. IARC (1997). *IARC monographs on the evaluation of carcinogenic risks to humans, Volume 69, Polychlorinated dibenzo-para-dioxins and polychlorinated dibenzofurans*. Lyon, France: International Agency for Research on Cancer.
23. Welton ML, Sharkey FE, Kahlenberg MS (2004). The etiology and epidemiology of anal cancer. *Surg Oncol Clin N Am* 13: 263-275.
24. Guenel P, Cyr D, Sabroe S, et al. (2004). Alcohol drinking may increase risk of breast cancer in men: a European population-based case-control study. *Cancer Causes Control* 15: 571-580.
25. Very rare cancers—a problem neglected (2001). *Lancet Oncol* 2: 189.
26. Lalami Y, Vereecken P, Dequanter D, et al. (2006). Salivary gland carcinomas, paranasal sinus cancers and melanoma of the head and neck: an update about rare but challenging tumors. *Curr Opin Oncol* 18: 258-265.
27. Gerard JP, Romestaing P, Ardiet JM, et al. (1995). [Current treatment of cancers of the anal canal]. *Ann Chir* 49: 363-368.
28. Stewart AK, Bland KI, McGinnis LS, Jr., et al. (2000). Clinical highlights from the National Cancer Data Base, 2000. *CA Cancer J Clin* 50: 171-183.
29. Johnson IG, Madeleine MM, Newcomer LM, et al. (2004). Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. *Cancer* 101: 281-288.
30. Fremgen AM, Bland KI, McGinnis LS, Jr., et al. (1999). Clinical highlights from the National Cancer Data Base, 1999. *CA Cancer J Clin* 49: 145-158.
31. Braithe F and Kurzrock R (2007). Uncommon tumors and exceptional therapies: paradox or paradigm? *Mol Cancer Ther* 6: 1175-1179.
32. Belkacemi Y, Zouhair A, Ozsahin M, et al. (2006). Prognostic factors and management of rare cancers. *Cancer Radiother* 10: 323-329.

Rosita Accardi

International Agency for Research on Cancer
150 cours Albert Thomas
69372 Lyon Cedex 08
France

Clement Adebamowo

Department of Surgery
College of Medicine, University of Ibadan
University College Hospital
Ibadan, Oyo State
Nigeria

Ben Anderson

Department of Surgery
University of Washington
Seattle, Washington 98195
USA

Philippe Autier

International Agency for Research on Cancer
150 cours Albert Thomas
69372 Lyon Cedex 08
France

Robert Baan

International Agency for Research on Cancer
150 cours Albert Thomas
69372 Lyon Cedex 08
France

Mariano Barbacid

Spanish National Cancer Research Centre (CNIO)
c/ Melchor Fernandez Almagro 3
28029 Madrid
Spain

Paolo Boffetta

International Agency for Research on Cancer
150 cours Albert Thomas
69372 Lyon Cedex 08
France

Mathieu Boniol

International Agency for Research on Cancer
150 cours Albert Thomas
69372 Lyon Cedex 08
France

Peter Boyle

International Agency for Research on Cancer
150 cours Albert Thomas
69372 Lyon Cedex 08
France

Jo Brady

Department of Medical Oncology
Churchill Hospital
Headington
Oxford, OX3
UK

Anne Brédart

Psycho-Oncology Unit
Curie Institute
26 rue d’Ulm
75246 Paris, Cedex 05
France

Paul Brennan

International Agency for Research on Cancer
150 cours Albert Thomas
69372 Lyon Cedex 08
France

Jean-Benoît Burriion

Institut Jules Bordet
1 rue Héger-Bordetstraat
1000 Brussels
Belgium

Elodie Caboux

International Agency for Research on Cancer
150 cours Albert Thomas
69372 Lyon Cedex 08
France

Franco Cavalli

Oncology Institute of Southern Switzerland
Ospedale San Giovanni
6500 Bellinzona
Switzerland

Young-eun Cho

Public Relations Team
National Cancer Center
809 Madu1-dong
Ilsandong-gu, Goyang-si
Gyeonggi-do
Republic of Korea

Gary Clifford

International Agency for Research on Cancer
150 cours Albert Thomas
69372 Lyon Cedex 08
France

Vincent Cogliano

International Agency for Research on Cancer
150 cours Albert Thomas
69372 Lyon Cedex 08
France

Maria-Paula Curado

International Agency for Research on Cancer
150 cours Albert Thomas
69372 Lyon Cedex 08
France

David Currow

Flinders University
Sturt Road
Bedford Park South Australia
Australia

Jean-Marie Dangou

Division of Prevention & Control of Noncommunicable
Diseases
WHO Regional Office for Africa
Cité Djoué, PO Box: 06
Brazzaville
Congo Republic

Ketayun Dinshaw

Tata Memorial Centre
E. Borges Marg., Parel
Mumbai 400 012
India

Sylvie Dolbeault

Psycho-Oncology Unit
Curie Institute
26 rue d’Ulm
75246 Paris, Cedex 05
France

Jean-François Doré

INSERM U 590
Centre Léon Bérard
28, rue Laennec
69373 Lyon Cedex 08

Mary Doroshen

National Colorectal Cancer Roundtable
American Cancer Society
www.nccrt.org

Eric Duell

International Agency for Research on Cancer
150 cours Albert Thomas
69372 Lyon Cedex 08
France

Mary Farfán

National Institute of Neoplastic Disease (INEN)
Av. Angamos 2520, Surquillo
Lima 34
Peru

Jill Farrington

Noncommunicable Diseases
WHO Regional Office for Europe (EURO)
Scherfigsvej 8
2100 Kobenhavn Ø
Denmark

Rodrigo Feijó

Divisão de Comunicação Social
National Cancer Institute (INCA)
Praca Cruz Vermelha 23, Centro
20230-130 Rio de Janeiro
Brazil

Jacques Ferlay

International Agency for Research on Cancer
150 cours Albert Thomas
69372 Lyon Cedex 08
France

Pietro Ferrari

Data Collection and Exposure Unit
European Food Safety Authority
Largo N. Palli 5/A
43100 Parma
Italy

Silvia Franceschi

International Agency for Research on Cancer
150 cours Albert Thomas
69372 Lyon Cedex 08
France

Pierre Hainaut

International Agency for Research on Cancer
150 cours Albert Thomas
69372 Lyon Cedex 08
France

Uzma Hasan

International Agency for Research on Cancer
150 cours Albert Thomas
69372 Lyon Cedex 08
France

Mia Hashibe

International Agency for Research on Cancer
150 cours Albert Thomas
69372 Lyon Cedex 08
France

Mary Heanue

International Agency for Research on Cancer
150 cours Albert Thomas
69372 Lyon Cedex 08
France

Julia Heck

International Agency for Research on Cancer
150 cours Albert Thomas
69372 Lyon Cedex 08
France

Zdenko Herceg

International Agency for Research on Cancer
150 cours Albert Thomas
69372 Lyon Cedex 08
France

Lisa-Maree Herron

Cancer Australia
Level 1 - Northbourne Avenue
lyneham, PO Box 1201
Dickson ACT 2602
Australia

Rayjean J. Hung

Samuel Lunenfeld Research Institute
60 Murray St.
Toronto M5T 3L9
Canada

Mazda Jenab

International Agency for Research on Cancer
150 cours Albert Thomas
69372 Lyon Cedex 08
France

Miklos Kasler

National Institute of Oncology
Rath Gyorgy u. 7-9
1122 Budapest
Hungary

David Kerr

Department of Clinical Pharmacology
University of Oxford
Old Road Campus Research Building
Off Roosevelt Drive
Headington, Oxford OX3 7DQ
UK

Namory Keita

Service de Gynécologie/Obstétrique
Université de Conakry
CHU Donka, route de Dixinn
B.P. 921 Conakry
Guinea

Heinrich Kovar

Children’s Cancer Research Institute
St. Anna Kinderkrebsforschung
Kinderspitalgasse 6
1090 Vienna
Austria

Carlo La Vecchia

Laboratory of General Epidemiology
Mario Negri Institute of Pharmacological Research
Via La Masa, 19
20156 Milan
Italy

Maria Leon-Roux

International Agency for Research on Cancer
150 cours Albert Thomas
69372 Lyon Cedex 08
France

Bernard Levin

2628 Broadway
New York
NY 10025
USA

Ni Li

International Agency for Research on Cancer
150 Cours Albert Thomas
69372 Lyon Cedex 08
France

Haifa Madi

WHO Regional Office for Eastern Mediterranean
and North African Region (EMRO)
P.O. Box 7608
Nasr City
Cairo 11371
Egypt

Patrick Maisonneuve

Epidemiology Unit
European Institute of Oncology
Via Ripamonti 435
20141 Milan
Italy

Kirsten McArdle

Department of Surgery
City Hospital
Dudley Rd
Birmingham B18 7QH
UK

James McKay

International Agency for Research on Cancer
150 cours Albert Thomas
69372 Lyon Cedex 08
France

Gordon McVie

Scientific Directorate
European Institute of Oncology
Via Ripamonti 435
20141 Milan
Italy

Richard Muwonge

International Agency for Research on Cancer
150 cours Albert Thomas
69372 Lyon Cedex 08
France

Maria-Claudia Nascimento

London School of Hygiene & Tropical Medicine
Keppel Street
London WC1E 7HT
United Kingdom

Twalib Ngoma

Ocean Road Cancer Institute
PO Box 3592
Dar es Salaam
United Republic of Tanzania

Hiroko Ohgaki

International Agency for Research on Cancer
150 cours Albert Thomas
69372 Lyon Cedex 08
France

Shigeru Omi

WHO Regional Office for the Western Pacific
(WPRO)
United Nations Avenue
PO Box 2932
Manila 1000
Philippines

Claudio Pelucchi

Laboratory of General Epidemiology
Mario Negri Institute of Pharmacological Research
Via La Masa, 19
20156 Milan
Italy

Luis Pinillos Ashton

National Institute of Neoplastic Disease (INEN)
Av. Angamos 2520, Surquillo
Lima 34
Peru

Samlee Plianbangchang

WHO Regional Office for South-East Asia (SEARO)
World Health House - Indraprastha Estate
Mahatma Gandhi Marg
New Delhi 110 002
India

Martyn Plummer

International Agency for Research on Cancer
150 cours Albert Thomas
69372 Lyon Cedex 08
France

Amelie Plymoth

International Agency for Research on Cancer
150 cours Albert Thomas
69372 Lyon Cedex 08
France

Qing Qing

Division of Environmental Health Sciences
Yale School of Public Health
60 College Street, PO Box 208034
New Haven, CT 06520-8034
USA

Kunnambath Ramadas

Regional Cancer Center
P.O. Box 2417
Trivandrum 695011
Kerala State
India

Giorgia Randi

Laboratory of General Epidemiology
Mario Negri Institute of Pharmacological Research
Via La Masa, 19
20156 Milan
Italy

Darius Razavi

Jules Bordet Institute
121 boulevard de Waterloo
Brussels 1000
Belgium

Sabina Rinaldi

International Agency for Research on Cancer
150 cours Albert Thomas
69372 Lyon Cedex 08
France

Ulrik Ringborg

Cancer Center Karolinska
Radiumhemmet
Karolinska University Hospital Solna
171 76 Stockholm
Sweden

Stefania Rizzo

European Institute of Oncology
Via Ripamonti 435
20141 Milan
Italy

Alan Rodger

Beatson West of Scotland Cancer Centre
Gartnavel General Hospital
Great Western Road
Glasgow
Scotland, UK

Mirta Roses

Regional Office for the Americas/Pan American
Sanitary Bureau (AMRO)
525, 23rd Street NW
Washington, DC 20037
USA

Massoud Samiei

Programme of Action for Cancer Therapy (PACT)
Department of Nuclear Sciences and Applications
International Atomic Energy Agency (IAEA)
Wagramerstrasse 5
PO Box 100
1400 Vienna
Austria

Rengaswamy Sankaranarayanan

International Agency for Research on Cancer
150 cours Albert Thomas
69372 Lyon Cedex 08
France

Catherine Sauvaget

International Agency for Research on Cancer
150 cours Albert Thomas
69372 Lyon Cedex 08
France

Ghislaine Scelo

School of Public Health
UC Berkeley
2150 Shattuck Ave., Suite 500
Berkeley, CA94704-7380
USA

Mary Jane Schier

M. D. Anderson Cancer Center
The University of Texas
1515 Holcombe Blvd
Houston, TX 77030
USA

Vladimir Semiglazov

N.N. Petrov Research Institute of Oncology
68 Leningradskaya Str., Pesochny 2
Saint Petersburg 197758
Russian Federation

Hai-Rim Shin

International Agency for Research on Cancer
150 cours Albert Thomas
69372 Lyon Cedex 08
France

Sudhir Srivastava

Cancer Biomarkers Research Group
Division of Cancer Prevention
National Cancer Institute
6130 Executive Boulevard, Suite 3142
Rockville, MD 20852
USA

Eva Steliarova-Foucher

International Agency for Research on Cancer
150 cours Albert Thomas
69372 Lyon Cedex 08
France

Kurt Straif

International Agency for Research on Cancer
150 cours Albert Thomas
69372 Lyon Cedex 08
France

Bakary Sylla

International Agency for Research on Cancer
150 cours Albert Thomas
69372 Lyon Cedex 08
France

Sean Tavtigian

International Agency for Research on Cancer
150 cours Albert Thomas
69372 Lyon Cedex 08
France

Massimo Tommasino

International Agency for Research on Cancer
150 cours Albert Thomas
69372 Lyon Cedex 08
France

Murat Tuncer

Cancer Control Department
Ministry of Health
Ilkiz Sokak No. 4/2
Sihhiye
06434 Ankara
Turkey

Lawrence von Karsa

International Agency for Research on Cancer
150 cours Albert Thomas
69372 Lyon Cedex 08
France

Joachim Weis

Department of Psychooncology
Tumor Biology Center at the University of Freiburg
Breisacher Str. 117
79106 Freiburg
Germany

Yi-Xin Zeng

Sun Yat-Sen University Cancer Center
651 Dongfeng Road East
Guangzhou 510060
China

Yawei Zhang

Division of Environmental Health Sciences
Yale School of Public Health
60 College Street, PO Box 208034
New Haven, CT 06520-8034
USA

Ping Zhao

Cancer Hospital and Institute
CAMS and Peking Union Medical College
17 South Pan Ji Yuan Lane
PO Box 2258
Beijing 100021
China

Tongzhang Zheng

Division of Environmental Health Sciences
Yale School of Public Health
60 College Street, PO Box 208034
New Haven, CT 06520-8034
USA

Subject index

1,3-butadiene 108-109, 119-120, 175, 178-179, 200

2,3,7,8-tetrachlorodibenzo-para-dioxin 174, 179, 496

2-naphthylamine 120, 174, 447

4,4'-methylenebis[2-chloroaniline] 176, 272

4-aminobiphenyl 116, 120, 175, 270, 447

4-(methylnitrosamino)-1-(3-pyridyl)1-butanol 114, 125

4-(methylnitrosamino)-1-(3-pyridyl)1-butanone 110, 114-116, 118-120, 124-125

5-fluorouracil 62, 66, 355

abasic site 203

acetaldehyde 114, 120, 136-138, 174, 182, 272, 330

acrylonitrile 120, 272

acute lymphoblastic leukaemia 468, 474-476, 478, 480, 483-484, 491

acute myeloid leukaemia 474-480, 483-484

acute promyelocytic leukaemia 479, 497

adenoma sebaceum 464

adrenocortical carcinoma 464, 484, 495

aflatoxin 108, 129, 138, 174, 179, 193, 195-196, 200, 350-354, 356-357

afro 16-17, 24, 27, 29, 42-43, 431

air pollution 123, 164, 178-181, 316, 393

alcohol dehydrogenase 136-137, 139, 182, 332, 337

alcohol drinking 7, 136-139, 155, 187, 333-335, 337, 356, 359, 391, 396, 414, 498

alkylating agent 62, 200, 207, 448, 474-475

aluminium production 177

anal cancer 129, 496-498

analgesic 80, 85, 187

anaplastic large cell lymphoma 472, 479

androgen 63, 140-145, 413, 428-429, 433, 435-436, 453-454

androgenic (anabolic) steroid 108

androgen receptor 63, 435-436

angiofibroma 464

angiogenesis 64, 66, 97, 191, 226-229, 283, 384, 409

angiomyolipoma 464

angiosarcoma 162, 174, 177, 272, 350, 495, 498

anthracycline 63, 386, 478

antibiotic 63, 65, 128, 154

antimetabolite 62, 65

antiretroviral 132, 279, 384

aortic aneurysm 110

apc 138, 182-183, 193, 198, 320-322, 343, 456-457, 464, 484, 489

apoptosis 63, 97, 128-129, 134-135, 140, 144, 167, 182, 192-193, 197, 204, 214, 216-222, 283, 353-354, 408

aromatic amine 109, 115, 271, 383, 444, 446-447

arsenic 108, 114, 120, 175, 179-181, 272, 447

arsenic and arsenic compound 175, 179

asbestos 108, 174-176, 178-181, 270-273, 280, 337, 390-392, 396, 441, 443

aspergillus 200, 351-352

aspirin 63, 221, 281, 283-284, 287, 360, 376, 378, 415, 417

astrocytoma 460, 462, 464-465, 484, 489, 492

ataxia telangiectasia 182-183, 185, 202-206, 216-217, 323, 363, 471, 477, 484

atb 363

atomic bomb 161, 392, 456, 463, 475

atrophic gastritis 347, 349

autoimmune disease 468

axillary freckling 464

bad 86, 90, 195, 217, 256, 267, 497

barrett oesophagus 341, 343

basal cell carcinoma 169, 322-323, 398, 403, 464, 484

base excision repair 200-203

bax 167, 217-218

bcl-2 217-218, 220-222

bcl-xl 217-218

behaviour 9, 30, 33, 40, 57, 68, 84, 86-88, 93, 100, 113, 115, 134, 147, 151, 156, 158, 166, 168, 190, 192, 240-242, 264-268, 325-326, 328, 370, 386-387, 390, 404, 419, 465, 468, 495

benz[a]anthracene 174

benzal chloride 176

benzene 108, 115, 118-120, 174-175, 178-180, 434, 436, 474-476, 485

benzidine 174-176, 447

benzo[a]anthracene 114

benzo[a]pyrene 110, 114, 116, 118, 120, 174, 178-180, 200, 272

benzo[b]fluoranthene 114

benzoyl chloride 176

beryllium 108, 175

beta-carotene 280-283, 285-287, 345, 391, 394

beta-catenin 192-193, 198, 226, 353, 462

betel quid 39, 124, 126, 330, 337

bidì 111, 330, 390

bidì 114-115

bile ducts 179, 350, 354, 366, 368

binge drinking 33, 138

biological resource centre 246-249, 252, 254, 256-257

bis(chloromethyl)ether 175, 272

bladder cancer 7, 18, 21, 23, 30, 132, 156, 180, 186, 237-239, 270-271, 366-373, 438, 444-449, 467

bleomycin 63, 65, 386

body mass index 33, 156, 158, 364, 371, 414, 426, 433, 443

bone metastase 72

brain cancer 170

brca1 68, 85, 90, 151, 182-185, 198, 204-206, 213, 217, 320-322, 324, 361, 363, 413-414, 417, 425, 454

brca2 68, 85, 90, 151, 182-183, 185, 198, 204-205, 320-324, 361, 363-364, 413-414, 417, 425, 454

breast cancer 7, 14, 17-18, 20-24, 31, 33-35, 38-39, 42, 63, 68, 70, 72, 83, 85, 90-93, 95, 100-103, 119, 123, 137, 140-142, 145-146, 149-158, 160-161, 176, 182-185, 191, 195, 197-198, 213, 215, 222, 225, 228-230, 232-234, 237, 239, 259-260, 280, 284-287, 296-301, 312, 320-324, 363, 365, 374, 376, 392, 404, 409, 411-417, 424-426, 428, 430, 435-437, 454, 489, 493-494, 496, 498

breast cancer screening 34, 100, 103, 296-298, 300-301

breast health global initiative 100-103, 301

bupropion 265, 267

burkitt lymphoma 128, 468-469, 472, 479, 483-484, 487

ca19-9 362

cadmium 108, 120, 175

café-au-lait spot 464

cancer registries 16, 20-21, 25, 30, 38, 40, 100, 188, 259, 288, 297, 325-326, 328, 338, 342, 347, 366, 399, 431, 439, 444, 460, 482, 488-489, 495, 498

cancer stem cell 7, 224, 228-229, 240-245, 408-410

cancer vaccine 278, 410

canthaxanthin 281

carbon monoxide 38, 63, 68-69, 77, 81-82, 89, 98, 101, 118-119, 122, 129, 132, 134, 141, 211-212, 246, 270, 305, 314, 350, 385, 419, 423, 453, 484

carcinogen identification 106, 108-109

cardiac rhabdomyomas 464

carotenoid 280-281, 286, 394, 454

caspases 216, 218-219

ccnd1 193, 198, 211, 214

cd44 227, 229

cdc25a 211

cdc25b 211

cdk2 211

cdk4 134, 211, 214, 322, 408, 410

cdkn2 182, 193, 197-198, 211, 213, 343, 354, 358, 361, 363, 408, 410

cdkn2a [p16ink4a] 343

cell adhesion 193, 226-227, 343, 347

cell cycle 7, 63, 128, 134, 167, 182, 193-194, 198, 200, 203-205, 208, 210-217, 219, 392, 400

cell cycle arrest 167, 182, 193, 203, 211, 216-217

cell cycle checkpoint 212

cell division 190-194, 196, 198, 210-211, 213-215

centers for disease control and prevention 30, 117, 123, 210, 365

c-erbB2 343

cerebrovascular disease 110

cervical cancer 7, 34-35, 43, 56-58, 61, 66, 76, 83, 100, 104, 128-129, 131, 133-135, 146-147, 149, 151-153, 186, 188, 259-260, 276, 278-279, 288-295, 304, 325-326, 330, 337, 384, 400, 418-423, 431, 437

cervical cancer screening 58, 61, 104, 152, 279, 295, 423

chemical carcinogen 33, 109, 117, 216

chemotherapeutic drug 38, 219

chemotherapy 31, 37, 39, 57, 62-66, 69-70, 72-74, 83, 85, 88, 92, 95, 97-98, 159, 186-187, 190-191, 218, 220, 228, 236, 243, 331, 355, 357, 362, 365, 380, 386, 409, 415, 422, 431, 460, 474-475, 477-478, 486, 496

chernobyl accident 160-161, 163, 456

chewing tobacco 124, 126

childhood malignancies 483, 487

chk1 213, 217

chk2 203, 213, 217, 484

chlorambucil 65

chloramphenicol 108

chlorinated toluenes 176

chlorination 180-181

chlorofluorocarbon 164, 180

chloroform 174, 180, 272

chloromethyl methyl ether 175

cholangiocarcinoma 129, 131-132, 350, 354-355, 357

choriocarcinoma 31, 65

chronic lymphocytic leukaemia 472, 474-475, 477-480

chronic myelogenous leukaemia 474, 479

chronic myeloid leukemia 480

chrysene 114

cigarette 12, 15, 31-32, 110-111, 114-115, 117, 119-121, 124-125, 139, 151, 187, 200, 208, 262-264, 268, 330, 332-335, 337, 364, 376, 378, 390, 392, 439-440, 442-443, 445-449

cirrhosis 128, 136-137, 186-187, 191, 350-353

classification of tumour 40-41, 383, 403, 443, 449, 463, 466, 472-473, 479-480, 493

clear cell carcinoma of the kidney 441

clinical trial 62-65, 67, 72, 86, 90, 149-150, 152, 155, 198, 220-221, 228, 238, 247, 254, 256, 265, 276, 279, 283, 286, 310, 357, 362, 373, 379, 395, 409, 411-412, 427, 486, 491, 497

coal-tar 108, 174-175, 177

colectomy 321, 324

colonoscopy 34, 96-98, 302-303, 321, 374

colorectal cancer 7, 15, 18, 20, 22-23, 26-27, 30-31, 34-35, 42-43, 63-66, 68, 70, 95, 97, 136, 138, 146, 148-150, 152, 154-158, 185-186, 190, 197, 207, 221, 234, 280, 283-287, 300, 302-303, 321-322, 324, 355, 363, 365, 374-379, 428, 464, 502

colorectal cancer screening 300, 303

common disease/ rare variant [cd/ rv] 184

comprehensive cancer centre 77, 373, 395, 411, 427

computerized tomography 37, 63, 73-74, 96-99, 273, 303, 314-317, 355, 360, 362, 396, 461, 486, 504

conjunctiva 130, 134, 407, 465-466

cowden syndrome 322

cox-1 282

cox-2 221, 282-283

creosote 108, 174, 176

crotonaldehyde 114

cryptorchidism 433-434, 436

crystalline silica 108, 272

Cutaneous angiofibroma ["adenoma sebaceum"] 464

cyclin a 211-212, 214

cyclin d 193, 198, 211, 214

cyclin dependent kinase 134, 193, 211-213

cyclin dependent kinase inhibitor 212-213

cyclin-dependent kinases 193, 211

cyclin e 215

cyclophosphamide 62-63, 65, 174, 448, 478, 480

cystic fibrosis 363

cytarabine 65

cytokines 159, 221, 227, 409, 468

dibenzo[*a,h*]anthracene 114

dibenzo[*a,l*]pyrene 114

diesel engine exhaust 108, 174, 176, 179

diet 7, 33, 57-58, 68, 82, 93, 154-159, 193, 195-197, 256, 280, 284-285, 287, 325, 335, 337, 343-345, 348, 356, 366, 374-376, 391, 396, 413, 417, 423, 425-426, 431, 443, 452, 454-457, 485

dietary fibre 221, 284, 376, 378, 413

diethylstilbestrol 434, 483, 487

diethyl sulfate 176

diffuse large b-cell lymphoma 472, 479

digital rectal examination 310

dimethylcarbamoyl chloride 176

dimethylphosphate 272

dimethyl sulfate 176

dioxin 175, 179-180, 471, 496, 498

dna adduct 62, 115-116, 272, 352

dna damage 7, 115, 137, 164-165, 167, 182, 191-192, 194, 200-203, 205, 207-209, 213-219, 222, 324, 352, 400, 413

dna ligase 201, 203

dna mismatch repair 321, 324, 363

dna repair 7, 116, 134, 136-138, 165, 167, 182, 186, 194, 200-209, 213, 222, 283, 324, 361, 392

dna unwinding 63, 205

dose-response 106, 117, 126, 162, 270, 338, 378, 439-440, 446, 498

dpc4 198, 358, 361, 363

drug resistance 409

dysplastic gangliocytoma of the cerebellum (lhermitte-duclos) 464

dysplastic naevus syndrome 406-407

e7 protein 330

e-cadherin 226, 228, 343, 347, 349

egf 64, 194, 361

egfr 193-194, 198, 343, 363, 460, 462

electromagnetic field 160, 170, 173, 475

emro 21, 24, 27, 29, 42-43, 259, 503

endometrial cancer 7, 98, 140, 142-143, 145-146, 148-151, 156, 187, 284, 320, 428-431, 453

endoscopic retrograde cholangiopancreatography 360

endoscopy 57

environmental pollution 7, 178-181, 431

environmental tobacco smoke 32, 118, 123, 179, 268

ependymoma 198, 462, 464

epichlorohydrin 176

epidermal growth factor 64, 66, 191, 193-194, 198, 361

epstein-barr virus 128-130, 132-135, 380-383, 385, 388, 468-469, 472-473, 479, 484, 490, 493

erbb2 198, 343, 363

erythroplakia 304-305

estrogen 63, 108, 136-137, 140-144, 146-147, 149-152, 284, 412-413, 417, 424, 426, 428-429, 432-436

estrogen receptor 63, 284, 435-436

estrogen therapy 429

ethic 253

ethylene oxide 109, 116, 175, 179

etoposide 63, 65, 386, 475

euro 22-24, 29, 31-35, 37-39, 42-43, 58, 63, 74, 80-81, 85, 90, 92-93, 98-100, 103, 109, 111-114, 116, 118-119, 121, 123-124, 128, 130, 137-138, 141, 145-147, 151-153, 158, 160-163, 169-170, 173, 179, 181, 187, 195, 198, 204, 215-216, 220, 240, 242, 245, 254, 256-257, 263-264, 268, 275-276, 279, 287, 289, 297-298, 300-302, 310, 313-314, 316, 320, 322, 330-337, 339-344, 346-347, 349-350, 353, 355, 357-358, 360-361, 364-367, 372-374, 376-379, 385-387, 390, 392-401, 403-404, 406-407, 410-412, 415, 417-418, 421, 423-426, 428, 430, 432, 434, 436-438, 440-441, 443-447, 449-450, 452, 455-464, 466-468, 470-471, 473-474, 476-478, 480, 482-489, 491-494, 497-498, 502-504

excision repair 200-203, 208

extracellular matrix 226-227

extracellular signal-regulated kinase 64

fac 443, 449

faecal occult blood test 302-303, 374

familial adenomatous polyposis 185, 283, 285, 287, 320-322, 324, 374, 376, 484

familial atypical mole syndrome 407

familial atypical multiple mole melanoma 363

familial breast cancer 85, 185, 363, 414, 417

familial pancreatic cancer 363

familial predisposition 324

fanconi anaemia 363, 484

fas 167, 217, 219, 343

fas ligand 167

fhit 343

fibroma 464

fine particle 180

fobt test 302

folic acid 280, 283, 285-286

follicular lymphoma 472, 479

food contaminant 174

formaldehyde 108-109, 114, 120, 175, 179-180, 447

framework convention on tobacco control 57, 118-119, 123, 188, 262, 268, 325

fruit 32-33, 58, 154-158, 281, 325, 328, 331, 335, 337-338, 340, 344-345, 348, 359, 375-376, 378, 391, 393-394, 413-414, 419, 425, 430, 441, 443, 447, 449

gamma-radiation 108, 160-163

gastric atrophy 344, 346

gastritis 135, 191, 277, 344-345, 347, 349

gene-environment interaction 246, 432

gene therapy 221, 231, 465

genetic instability 208, 210, 213

genetic susceptibility 7, 40, 182-183, 185, 192, 246, 332, 335-337, 339, 347, 380-382, 390, 419, 432, 435, 490

genomic instability 207, 213, 215

germ cell tumour 65-66, 436, 488-490, 492-493

germline mutation 68, 320-321, 324, 347, 349, 408, 410, 460, 465

glioblastoma 197-198, 409, 460-465, 489

glioma 40, 163, 170-171, 173, 198, 460-464, 484, 492

globocan 2000 151

gorlin syndrome 322, 484

growth factor 62, 64, 66, 134, 140-143, 145, 187, 190-193, 198, 217, 221, 227, 343, 361, 364, 424, 426, 453, 455

haemangiosarcoma 162, 272

haematuria 272, 422

haemochromatosis 352

hamartoma 464

hamartomas 464

head and neck cancer 7, 74, 136, 139, 182, 198, 330-331, 333, 335, 337

health care disparities 100-101

helicobacter pylori 108, 128-129, 131, 133-135, 154, 186, 274, 279, 286, 325, 343-349, 449, 469, 490

hepatitis 9, 32, 34-35, 43, 57, 108, 128, 130-131, 134-135, 174, 186, 188, 195, 248, 255, 274-275, 279, 325-326, 350, 353-354, 357, 387, 437, 490

hepatocellular carcinoma 76, 128, 131, 135-137, 146, 197, 199, 272, 274-276, 279, 350-355, 357

her-2 191, 198

hereditary nonpolyposis colorectal cancer 70, 207, 320-322, 324, 363, 374, 430

hereditary pancreatitis 186-187, 358-359, 363

herpesvirus 131, 383-385, 388, 473

heterocyclic amines 359, 375

hhr23b 201-202

hmlh1 185, 207, 464

hmsh2 185, 207

hmsh6 207

hnpcc 70, 320-322, 324, 363, 374, 430

hodgkin disease 31, 130, 484-485

hormonal therapy 83, 151, 424

hormone replacement therapy 140, 142, 146, 148-152, 186-187, 367, 376, 412-414, 428-430

hot beverage 338, 340, 343

hpms2 207

h-ras 134, 167

htlv1 128, 134

htlv-1 129-131, 490

human genome project 230

human herpes virus-8 129, 384-385, 388

human immunodeficiency virus 17, 128, 130-135, 174, 248, 255, 259, 274, 277-279, 384-388, 403, 419, 423, 469-470, 473, 484, 490, 496

human papillomavirus 9, 43, 57-58, 61, 108-109, 128-135, 146-147, 151, 186, 188, 274, 276-279, 288-295, 325-326, 330-331, 337, 400, 403, 418-421, 423, 437, 496

hypoxia 216, 253

iarc handbooks of cancer prevention 103, 117, 158, 169, 268, 281, 286, 295, 301, 394, 443

iarc monograph 39, 106-109, 114, 116-119, 123, 126, 129, 139, 148, 151, 163, 169, 173, 175-177, 181, 208, 279, 287, 333, 337-338, 349-350, 357, 383, 388, 394, 403, 410, 418, 423, 443, 449, 451, 455, 473, 498

immunodeficiency 130, 174, 248, 255, 274, 277, 279, 384, 400, 468, 471, 473, 484, 490

immunosuppression 278, 388, 405, 419, 423

immunotherapy 409

imprinting 196, 483, 487

indomethacin 281, 283

infection 7, 9, 13, 15, 26, 31-32, 34-35, 39, 56-57, 61, 66, 68, 82, 128-135, 137, 146-147, 151, 186, 188, 274-277, 279, 289, 291, 325, 330-331, 343-351, 353-357, 360, 367-368, 370, 380-381, 385-388, 400, 403, 418-421, 423, 435, 437, 440, 444, 448-449, 468-469, 476, 478, 484, 490, 493

inflammatory bowel disease 186, 374

insulin-like growth factors 141-145, 426, 453

integrin 225-229

international agency for research on cancer 4-5, 9, 14-16, 27, 29, 38-41, 43, 61, 79-80, 103, 106-109, 114, 116-120, 123, 126-127, 129, 131, 139, 146-148, 151, 155-156, 158-159, 162-164, 167, 169, 172-177, 179, 181, 194, 199-200, 208, 246, 256-257, 262, 268, 271-273, 279-281, 283-284, 286-288, 295, 299-301, 303, 307, 314-315, 333, 336-338, 340, 343, 345, 349-350, 355, 357, 364, 368, 372, 378, 383, 388, 394-395, 397, 400, 403, 410, 417-418, 423, 426, 430-431, 436, 440, 443, 449, 451, 455, 459, 466, 473, 480, 487, 493, 498, 502-504

interval cancer 298

intrahepatic cholangiocarcinoma 350, 354-355

invasivenes 246

ionizing radiation 96-97, 160-161, 163-164, 173, 192, 200, 202, 217, 220, 273, 297, 392, 394, 456-457, 463, 474-475

ipos 89-91

iris hamartomas 464

ischaemic heart disease 137

isochromosome 462

jaw cyst 464

kaposi sarcoma 7, 9, 17, 128-130, 132, 186, 278, 384-387, 389, 431, 494

kidney cancer 7, 137-138, 156, 438-443

kip1 211

k-ras 167, 186-187

laparoscopy 302, 360

laryngeal cancer 72, 116, 330, 333-335, 337

latent period 106

leukaemia 7, 31, 38, 63, 65, 110, 119, 128-129, 153, 160-162, 170, 172, 177, 179-180, 187, 197-198, 221, 260, 323, 460, 464, 468, 470, 472, 474-484, 486-492, 497

leukoplakia 304-305

li-fraumeni syndrome 196, 322, 460, 465, 484, 495, 498

linear accelerator 72-74

liver cancer 7, 9, 17, 20, 22, 34-35, 42, 132-133, 137, 146, 161, 186-188, 194-196, 198, 271-272, 277, 326, 350-355, 357

liver fluke 129, 131-132, 325, 349-350, 354, 357, 449

liver transplantation 355

lkb1 361, 363

lobular carcinoma in situ 415

low- and middle-income countries 7, 25, 39, 100-103, 127, 338

low grade diffuse astrocytoma 462

lung cancer 7, 12-13, 17-18, 20-24, 30-32, 35, 42, 57, 64, 74, 90-91, 110, 112-119, 123-124, 126, 136-137, 149-150, 152-153, 161, 174, 178-181, 186, 188, 194, 198, 214, 230, 233-234, 239, 262-263, 265-266, 271-272, 280-282, 286, 316-317, 325, 390-395, 404, 461, 494

lycopene 281, 283, 453-455

lymphangioliomyomatosis 464

lymphoma 7, 18, 63, 65, 69, 97, 128-132, 135, 137, 153, 176, 179, 187, 198, 216, 218, 260, 277-278, 323, 345, 365, 384, 388, 467-473, 475, 479-480, 482-490, 492-493, 495, 497

lymphoplasmacytic lymphoma 479

magnetic resonance imaging 37, 62-63, 85, 96-97, 99, 314-315, 360, 381, 416, 424, 461, 463, 471, 486

malaria 259, 484

malt lymphoma 472, 479

mammogram/mammography 32, 34, 85-86, 187, 296-301, 412, 415-417

mantle cell lymphoma 472, 479

mastectomy 31, 68, 72, 83, 85-86

matrix metalloproteinases 227, 229

mdm2 198, 217, 460

meat 154-158, 338, 364, 378, 391, 425, 430, 441, 451-452, 455

medical exposure 160

medical oncology 7, 37-38, 62-63, 65, 67, 103, 502

medulloblastoma 460, 462-464, 484, 489

melanoma 7, 18, 33, 37, 65, 83, 90, 97, 129-130, 134, 164-169, 182-183, 185, 213, 225, 282, 318-319, 322-323, 363, 398-411, 465, 467, 488-490, 492-494, 497-498

men1 322

meningioangiomatosis 464

meningioma 171, 198, 322, 460-461, 463-464, 484, 495

mesothelioma 7, 178, 186, 238, 271, 396-397

met 78, 109, 237-238, 252, 294, 442

meta-analyses 93, 95, 283, 348, 449

metabolic activation 116

metal 108, 114-115, 124, 174-176, 179-180, 360, 390

metastasis 7, 40, 62, 69, 182, 187, 224-229, 241, 354, 399, 409

methotrexate 62-63, 65

methylenetetrahydrofolate reductase 138

methyl methanesulfonate 176

microarray 231

micronutrient 280, 282-283, 348, 413, 419, 447

microsatellite 207-208, 237-239, 321, 324, 374, 428

microsatellite instability 208, 238, 321, 324, 374, 428

microwave 160, 170-172, 463

migration (cellular/population) 35, 59, 158, 205, 226-228, 386, 409, 428

minimal residual disease 478

mining 175-178, 396

mirna 230-231, 234

mismatch repair 185, 207, 321, 324, 363, 374

mitogen activated protein kinase 64, 221

mitomycin c 62

mitotic inhibitor 63

mlh1 182, 320-322, 324, 361, 363, 484

mmacl 464

mmp 227

mobile telephone 170-171

molecular epidemiology 139, 194, 246, 357, 361, 386

mpnst 464, 484

msh2 182-183, 320-322, 324, 361, 363, 484

multiple basal palmar and plantar pits 464

multiple endocrine neoplasia 68, 322, 456-457

multivitamin 283, 286

mustard gas [sulfur mustard] 174-175, 330

mutation hotspot 208

myc 182, 193, 216, 233, 408, 462, 484

mycotoxin 339, 351, 383

myeloma 13, 38, 65, 161, 468, 479

naevi 404-408, 410

naevoid basal cell carcinoma syndrome [garlin] 464

nasopharyngeal cancer 383

national cancer control programmes 57, 61, 89, 188, 259, 326, 395, 437

necrosis 128, 134-135, 216-218, 253, 463

nerve gliomas 464

nervous system tumours 460, 462-463, 487

neuroblastoma 198, 215, 220, 460, 462, 483-485, 487, 494, 498

neurofibromas 464

neurofibromatosis 322, 460, 462, 464, 484

neutropenia 62-63, 90, 479

nf1 322, 460, 462, 464, 484

nf2 322, 460, 464, 484

nickel compounds 175

nicotine replacement therapy 265, 267

nitric oxide 218, 222

nitrogen dioxide 115, 270

nitrosamine 39, 109-110, 114-115, 118-119, 124-126, 138, 337, 339, 360, 382, 394, 485

nitrosoureas 62, 463

n-nitrosamines 114, 126, 382, 394

n'-nitrosoanabasine 114

n-nitroso compounds 135, 463

n-nitrosodiethylamine 114

n-nitrosodimethylamine 114, 116

n'-nitrosonor nicotine 114, 116

nodal marginal zone lymphoma 472, 479

non-alcoholic fatty liver disease 352, 354, 356

non-familial malignant melanoma 406

non-hodgkin lymphoma 130, 132, 137, 216, 278, 384, 468, 471, 473, 484-485, 489-490

non-intentional sun exposure 166-168

non-melanoma skin cancer 7, 129, 134, 167, 282, 398-403

nonsteroidal anti-inflammatory drugs 283, 286, 376, 378, 415

n-ras 167

nucleotide excision repair 200-202, 208

o6-alkylguanine-dna-alkyltransferase 207

o6-methylguanine 126, 207

obesity 7, 9, 15, 27, 32-33, 68, 70, 140, 142, 145, 154-157, 159, 325, 338, 340, 343-344, 352, 354, 357, 359, 364, 366-368, 370, 372, 375, 378, 414-415, 424-425, 428, 430, 437-438, 440, 442-443, 453

occupational carcinogen 119, 174, 270-272, 316, 326, 337, 443, 449

occupational exposure 7, 9, 57, 123, 160-161, 170, 174-175, 177-178, 271, 273, 393, 396, 400, 403, 441, 443-444, 448, 456, 463, 475, 495

oesophageal cancer 22, 72, 115, 262-263, 282, 335, 338, 340, 343

omega-3 fatty acids 284, 287, 452, 455

oncogene 68, 134-135, 145, 167, 182, 185, 190-192, 197-198, 208, 214-216, 221-222, 226, 229, 231, 233, 276, 361, 363-364, 377, 383, 408, 428, 442, 457, 467, 484, 487

oophorectomy 68, 320, 324

opioid analgesic 80, 85

opisthorchis viverrini 129, 131

optic nerve glioma 464

oral cancer 7, 20, 115-116, 124, 197, 304-307, 330-333, 337, 340-341

oral cancer screening 304-307

oral contraceptive 4, 7-9, 12-16, 24, 26-40, 42-43, 56-66, 68-74, 76-78, 80-104, 106-110, 112-120, 123-124, 128-162, 164-188, 190-194, 196-208, 210-214, 216-234, 236-243, 246-260, 262, 264-265, 267-283, 285-286, 288-292, 294-299, 301-304, 307, 310-311, 313-316, 318-326, 328, 330-341, 343-362, 364-369, 374-376, 378-379, 381-400, 403-415, 417-436, 438, 440-457, 460-465, 467-480, 482-495, 497-498, 502-504

osteosarcoma 13, 210, 322, 483-484, 488-490, 492-493, 495

ovarian cancer 7, 31, 62-63, 68, 90-91, 97, 140, 143, 145, 147-149, 151-152, 158, 182, 185-187, 198, 239, 302, 313-315, 320, 322, 324, 424-427

ovarian fibromas 464

overweight 9, 57, 70, 140, 149, 154, 156-157, 328, 367, 370, 415, 424-425, 429, 440, 443

ozone 164, 169, 178, 180, 270, 471

p14arf 193, 213, 408

p16/cdkn2a 358, 361, 363

p16ink4a 134, 197, 343, 408

p19arf 211

p53 mutation 194-196, 199, 220, 353-354, 428, 460, 462, 478, 489

paho 17-19, 29, 42-43, 104

palliative care 7, 56-57, 60, 65, 69-70, 76-81, 83, 87, 90, 104, 259, 325-326, 389, 431, 437, 478

pancreas cancer 7, 35, 186, 283, 358-363, 365

pancreatic cancer 30, 124, 136-137, 186-187, 197-198, 286, 358, 361-364, 453

pancreatitis 137, 186-187, 358-360, 363

panin 187, 358, 361

patched 167

peptic ulcer 131, 277, 345

peritoneum 178-179, 224, 354, 396

pesticide 175-176, 180, 272, 360, 414, 434, 463, 468, 471, 485, 496

petroleum 108, 177, 179, 441, 447

phaeochromocytoma 464

pharyngeal cancer 20, 116, 124, 263, 333, 383

phenacetin 108, 186-187, 448

philadelphia chromosome 474, 476

phosphoinositide-3-kinase 203

pilocytic astrocytoma 462

piroxicam 281, 283, 287

platelet derived growth factor 198, 460

platelet derived growth factor receptor 460

pleura 175, 178-179, 396

pms1 322

pms2 321, 363, 484

poly(adp-ribose)polymerase 203, 222, 320

polychlorinated biphenyl 176, 179-180, 434, 436, 447

polycyclic aromatic hydrocarbons 109-110, 114-115, 124, 174, 272, 360, 403, 441, 447

polymerase chain reaction 237-238, 258, 385

polymorphism 136-137, 332, 334, 336, 348-349, 352, 364, 413, 435-436

polynucleotide kinase 203

positron emission tomography 62-63, 97-99, 314-315, 365, 461

prb 134, 198, 211-212, 216, 219

prednisone 475

procarbazine 65, 475

progesterone 140-142, 413, 428-429

progesterone receptor 140, 413

prognostic factor 343, 480, 496-498

promoter hypermethylation 197, 363

prostaglandin 282, 287

prostate cancer 7, 17-18, 23, 30, 35, 42, 63, 83, 85, 90, 93, 99, 104, 137, 142-145, 154-158, 182-183, 185, 211, 230, 233-234, 237, 239, 280-283, 286, 310-313, 323, 450-455

prostate cancer screening 310, 312-313

prostate specific antigen 234, 237, 310, 313, 450-451, 454

protease 216, 218-219, 227, 234, 343

protein kinase c [pkc] 221

proteolysis 215, 227

proteomic 230-231, 234, 236, 239, 247, 250, 253, 256, 258, 315-317, 354, 427

proto-oncogene 68, 167, 197, 221, 457

psycho-oncology 7, 82-83, 85, 87-91, 93, 95, 502

ptch 322, 462, 464, 484

radiotherapy 7, 14, 35-39, 57-58, 60, 62, 65, 72-75, 88, 97-99, 104, 127, 159-160, 186-187, 191, 202, 313, 331, 355, 365, 380, 386, 392, 411, 422-423, 431, 475, 483, 490, 496

radon 108, 161-163, 174-175, 177, 179-181, 390, 392-393

ras 64, 134, 167, 182, 186-187, 193, 198, 216, 221, 428

rb1 192-193, 198, 211, 322, 484

reactive oxygen species 115, 354

recombination 131, 201, 203-206, 208, 213, 215, 324

rehabilitation 7, 37, 56, 69, 76, 92-95, 159, 395

renal cell carcinoma 440-441, 443, 464

ret 68, 198, 322, 457

retinal haemangioblastomas 464

retinoblastoma 134, 182, 192, 198, 210-212, 215-216, 322, 460, 465, 482-484, 486

retinoic acid 222, 281

retinoid 280-281, 286

rural area 88, 124, 179

salicin 284

salt 250, 345, 381-382

sarcoma 7, 9, 13, 17, 31, 40, 62, 65, 74, 128-132, 161-162, 174, 177, 186, 198, 210, 225, 272, 278, 322, 350, 370, 383-389, 431, 464, 473, 479-480, 482-484, 486, 488-498

schistosoma haematobium 128-129, 132, 444, 448

schwannoma 198, 460, 463-464

searo 20-21, 24, 27, 29, 42-43, 503

secondary glioblastoma 460

selenium 280-282, 285-286, 375, 450, 454-455

seminoma 65-66, 432, 435-436, 497

senescence 210, 214, 216, 408

shade 164, 167-168

shh 167

sigmoidoscopy 302-303, 374

silica 108, 174-175, 179, 272

single nucleotide polymorphism 183-184, 230, 232-233, 336, 383

siRNA 231

skin cancer 7, 33, 129, 134-135, 164-165, 167, 169, 180, 187, 192, 201, 282, 286, 319, 398-403, 408, 410

smad4 361, 363

small cell lung cancer 74, 90-91

smoke 31-33, 39, 108, 110-111, 114-115, 117-121, 123, 174, 179-181, 200-201, 262-264, 267-268, 333, 335, 337, 382-383, 390, 394, 443, 445, 447, 455, 463, 466, 476

smokeless tobacco 7, 109, 114, 124-127, 337, 390, 394

smoking cessation 82, 93, 116, 262, 264-268, 317, 334, 376, 439, 448

snuff 14, 124, 126

soil pollution 180

solar radiation 108, 162, 164, 174, 179-180, 400, 465

somatic mutation 374, 443

soot 108, 174-175

spinal ependymomas 464

spinal tumour 462

spiral ct 96, 316

squamous-cell carcinoma 33, 130, 136, 151, 169, 187, 280, 286, 289, 305, 323, 330, 332, 334, 336-338, 343, 380, 382-383, 390, 398, 400, 403, 418-419, 421-423, 444

stem cell 7, 93, 215, 224, 228-229, 240-245, 379, 408-411, 476, 478

steroid hormone 63, 143, 145, 151, 429, 435, 455

stk11 322, 361, 363

stomach cancer 7, 9, 14, 18, 20, 22-23, 42, 104, 115, 137, 154, 180, 188, 198, 218, 282, 285, 308-309, 344-347, 349

subependymal giant cell astrocytoma 464, 484

subungual fibroma 464

sulfur dioxide 270

sulindac 281, 283-285, 287

sunburn 164-165, 167-169, 399-400, 403, 405

sunlight 7, 9, 33, 164-167, 169, 201, 403-406

sunscreen 164, 167-169, 286

surgical implant 187

tamoxifen 31, 63, 108, 280, 284-285, 287, 355, 415, 417, 430

taxane 63, 386

tcdd 174, 179, 496

t-cell 128, 130, 132, 204, 216, 227, 277-279, 385-386, 468-470, 472-473, 478-479, 490

telemedicine 60, 70

telomerase 128, 135, 192, 213-215

telomere 128, 192, 213-215, 361

teniposide 475

testicular cancer 7, 39, 65, 432-437, 494

testosterone 63, 140-141, 143, 413, 432-433, 435-436, 453, 455

tetrachloroethylene 176, 179

tgf-alpha 361

tgf-beta 361

thioguanine 62

thyroid cancer 7, 70, 160-163, 198, 322, 456-457, 459, 483, 487, 493-494

thyroidectomy 68

tnm staging 254

tobacco 7, 9, 15, 26-27, 30-33, 35, 38-39, 42-43, 57, 61, 76, 104, 108-111, 113-119, 121, 123-127, 136-139, 146, 154, 174, 178-181, 188, 201, 262-269, 306-307, 325, 328, 330, 333-339, 343, 354, 356-358, 361, 364, 378, 382-383, 390-394, 396, 414, 417, 419, 423, 431, 437-438, 442-444, 446-451, 455, 463, 466, 476

tobacco advertising 264-265

tobacco control 7, 9, 15, 30, 35, 38, 42, 57, 61, 104, 117-119, 123, 126, 188, 262-263, 265, 267-269, 325, 390, 437

tobacco free initiative 117

tobacco smoke 32, 39, 108, 110, 114-115, 117-119, 121, 123, 174, 179-181, 201, 264, 268, 333, 337, 383, 390, 394, 443, 448, 455, 463, 466

tobacco specific nitrosamine 110, 114-115, 118-119, 124-126

toluene 176

topoisomerase 63, 200

trail 217, 221-222

trails 217, 221-222

trichilemmomas 464

trichloroethylene 108, 174, 176, 179, 272, 443

tsc1 460, 464, 484

tsc2 460, 464, 484

tuberous sclerosis 460, 464, 484

tumour suppressor gene 167, 182, 190, 197-198, 213, 217, 226, 231, 343, 361, 363-364, 408, 428, 441, 465

tunel assay 220

tyrosinaemia 352

uicc 37, 39-40, 70, 127, 159, 408, 431

ulcerative colitis 186

ultrasound 96, 298, 314-315, 367

ultraviolet radiation 7, 160, 162, 164-167, 169, 179, 400, 404-405, 410, 471

upa 227, 343

uracil 201

urocanic acid 167

vaccine 34, 56, 61, 128-129, 159, 188, 221, 248, 265, 268, 274-279, 295, 326, 347, 355, 357, 396, 409-410, 420-421, 423, 490, 493

vascular endothelial growth factor 64, 134, 221, 227

vasectomy 435

vegetable 32-33, 58, 154-158, 325, 328, 331, 335, 337-338, 340, 344-345, 348, 359, 375-376, 378, 391, 393-394, 413-414, 419, 425, 430, 441, 443, 447, 449, 452, 457, 459

vhl 198, 322, 441-442, 460, 464

vinblastine 63, 65, 386

vinca alkaloids 63, 65

vincristine 63, 65, 386, 475, 478

vinyl chloride 108-109, 174-175, 177, 271-273, 495, 498

virtual colonoscopy 97-98, 302-303, 307, 403

vitamin a 137, 280-281, 283, 285-286, 394

vitamin d 158, 166, 280, 283, 285-287, 375, 454

vitamin e 280-283, 285-286, 345, 394, 450, 454-455

von hippel-lindau disease 443, 460

western lifestyle 100

whipple procedure 362

who framework convention on tobacco control 57-58, 118, 123, 188, 262, 264-265, 268, 325, 437

who global burden of disease project 136-137

who regional office 431, 437, 502-503

wilms tumour 323, 482-484

wood dust 108, 175, 382

world health organization 4, 8, 12, 14, 16-25, 27, 29-30, 32-37, 39-43, 56-61, 63-66, 68, 72, 77-82, 85-87, 89-90, 92, 95-96, 99, 107-108, 110-111, 113, 115, 117-121, 123-124, 126-127, 134-139, 141-142, 146-149, 156, 159, 161, 165, 168, 178-181, 188, 195-196, 201, 209, 225, 237, 246-248, 254-256, 259, 262-265, 268, 272, 274-276, 282, 291, 299, 302, 307-308, 310-311, 319-321, 323, 325-327, 335, 338, 345, 347-348, 367, 369, 380, 382-386, 390, 403, 406-407, 412, 414, 416, 425, 428, 430-431, 435, 437, 439, 443, 445-446, 449, 454, 462-463, 466, 472-475, 477, 479-480, 483, 485-486, 493, 498, 502-503

wpro 21-22, 24, 27, 29, 42-43, 503

xeroderma pigmentosum 165, 201-202, 208, 323

xlp 323

xpb 201-202, 323

xpc 201-202, 323

xpg 201-202, 323

x-radiation 394